On January 5, 2024, Avidity Biosciences, Inc. announced that it plans to initiate the global Phase 3 HARBOR trial of AOC 1001 for adults living with myotonic dystrophy type 1 (DM1), in mid-2024. The Company plans to provide first look data for the efficacy of AOC 1001 from the MARINA-OLE study of AOC 1001 in the first quarter of 2024. Regarding AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy, the Company plans to provide data from a preliminary assessment of approximately half of patients in the FORTITUDE trial in the second quarter of 2024.

As previously disclosed, the Company plans to provide a first look at AOC 1044 data from the EXPLORE44 trial of people living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping, in the second half of 2024.